Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

Register now for this interactive, case-based workshop series to hear about how to effectively incorporate newly approved and emerging agents and treatment combinations into the care of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). After the meeting, download the associated slideset for use in your clinic. 

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


• Introduction

• Case Discussions: Individualizing Care of Patients with CLL/SLL

- Key Variables in Making Treatment Decisions
- Classes of Agents: Mechanism of Action, Selectivity, Specificity and Associated Adverse Events
- Recent Data on Advances in the Treatment of CLL/SLL
- Optimal and effective management of CLL/SLL

Partnering With Patients in Their Care

- Discussing Patient Treatment Goals and Expectations
- Best Practices in Patient Care
- Effective Communication of New or Worsening Symptoms with Healthcare Professionals

• Final Thoughts and Audience Question and Answer Session


Date / Time
Event Details


Jennifer Brown, MD, PhD

Worthington & Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director and Institute Physician, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Jeff Sharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Program Overview
This program will provide expert perspectives to facilitate state-of-the-art clinical management strategies for patients with CLL/SLL, including information on the latest practice impacting data on recent advances in the personalization of care for patients with CLL/SLL.

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of multidisciplinary team learners in the care of patients with CLL using evidence-based and guideline-directed best practices.

Target Audience
This program is intended for community-based medical hematologists/oncologists, nurses, pharmacists, advanced practice providers, and other healthcare professionals involved in the treatment of patients with CLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration available clinical data, the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
  • Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL
  • Develop multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial-related and age-related disparities in care
  • Manage treatment-related symptoms in patients with CLL/SLL using guidelines and expert recommendations based on real-world experience to optimally adjust, discontinue, or change the patient’s current therapeutic plan 
  • Evaluate the evolving role of measurable/minimal residual disease, allogeneic hematopoietic cell transplant, CAR T-cell therapy, and other novel therapeutics for CLL/SLL


Joint Accreditation Statement

 In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-012-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.